{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T03:04:09Z","timestamp":1781406249460,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.eplepsyres.2006.05.013","type":"journal-article","created":{"date-parts":[[2006,7,4]],"date-time":"2006-07-04T17:10:51Z","timestamp":1152033051000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy"],"prefix":"10.1016","volume":"71","author":[{"given":"Luigi Maria","family":"Specchio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Teresa","family":"Giallonardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Specchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Boero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"La Neve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2006.05.013_bib1","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1528-1157.1998.tb01332.x","article-title":"Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy","volume":"39","author":"Beran","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib3","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/archneur.62.11.1705","article-title":"Topiramate in patients with juvenile myoclonic epilepsy","volume":"62","author":"Biton","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib4","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1212\/01.wnl.0000187118.19221.e4","article-title":"Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures","volume":"65","author":"Biton","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1059-1311(96)80110-5","article-title":"The use of lamotrigine in juvenile myoclonic epilepsy","volume":"5","author":"Buchanan","year":"1996","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib6","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1212\/WNL.56.10.1424-a","article-title":"Exacerbation of juvenile myoclonic epilepsy with lamotrigine","volume":"56","author":"Carrazana","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1684\/j.1950-6945.2005.tb00127.x","article-title":"Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes","volume":"7","author":"Di Bonaventura","year":"2005","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.0013-9580.2004.39503.x","article-title":"Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy","volume":"45","author":"Gallagher","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/jnnp.70.2.240","article-title":"Clinical factors of drug resistance in juvenile myoclonic epilepsy","volume":"70","author":"Gelisse","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib11","series-title":"Juvenile myoclonic epilepsy: the Janz syndrome","first-page":"11","article-title":"Juvenile myoclonic epilepsy today: current definitions and limits","author":"Genton","year":"2000"},{"issue":"Suppl. 7","key":"10.1016\/j.eplepsyres.2006.05.013_bib12","first-page":"187","article-title":"Open study on the efficacy of levetiracetam monotherapy in idiopathic generalized epilepsy","volume":"43","author":"Hirsch","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib13","doi-asserted-by":"crossref","unstructured":"ILAE, 1989. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30, 389\u2013399.","DOI":"10.1111\/j.1528-1157.1989.tb05316.x"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1600-0404.1985.tb00900.x","article-title":"Epilepsy with impulsive petit mal (juvenile myoclonic epilepsy)","volume":"72","author":"Janz","year":"1985","journal-title":"Acta Neurol. Scand."},{"issue":"Suppl. 8","key":"10.1016\/j.eplepsyres.2006.05.013_bib15","first-page":"153","article-title":"Promising results of levetiracetam in juvenile myoclonic epilepsy","volume":"43","author":"Jongsma","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0920-1211(96)00031-9","article-title":"Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam","volume":"25","author":"Kasteleijn-Nolst Trenit\u00e9","year":"1996","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(98)00410-5","article-title":"Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy","volume":"353","author":"Klitgaard","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1684\/j.1950-6945.2004.tb00075.x","article-title":"Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy","volume":"6","author":"Kothare","year":"2004","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1059-1311(03)00139-0","article-title":"Levetiracetam treatment of idiopathic generalized epilepsy","volume":"12","author":"Krauss","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.seizure.2003.06.001","article-title":"Levetiracetam as add-on therapy in generalised epilepsies","volume":"13","author":"Kumar","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib21","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"P.N.A.S."},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib22","series-title":"Antiepileptic Drugs","first-page":"419","article-title":"Levetiracetam: mechanisms of action","author":"Margineanu","year":"2002"},{"issue":"Suppl. 8","key":"10.1016\/j.eplepsyres.2006.05.013_bib23","first-page":"153","article-title":"Levetiracetam in idiopathic generalised epilepsies","volume":"43","author":"Meencke","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00128072-200103050-00006","article-title":"Treatment of typical absence seizures and related epileptic syndromes","volume":"3","author":"Panayiotopoulos","year":"2001","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib26","first-page":"1","article-title":"Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions","volume":"13","author":"Patsalos","year":"2004","journal-title":"Rev. Contemp. Pharmacother."},{"issue":"Suppl. 4","key":"10.1016\/j.eplepsyres.2006.05.013_bib27","first-page":"19","article-title":"Juvenile myoclonic epilepsy: long-term response to therapy","volume":"30","author":"Penry","year":"1989","journal-title":"Epilepsia"},{"issue":"Suppl. 3","key":"10.1016\/j.eplepsyres.2006.05.013_bib28","first-page":"A294","article-title":"Levetiracetam monotherapy in the treatment of convulsive seizures in patients with juvenile myoclonic epilepsy","volume":"58","author":"Resor","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib29","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl. Florence 2000","key":"10.1016\/j.eplepsyres.2006.05.013_bib30","first-page":"39","article-title":"Levetiracetam, a promising option for treatment of juvenile myoclonic epilepsy","volume":"41","author":"Smith","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11940-004-0015-6","article-title":"Idiopathic generalized epilepsy","volume":"6","author":"Sullivan","year":"2004","journal-title":"Curr. Treat. Options Neurol."},{"issue":"Suppl. 6","key":"10.1016\/j.eplepsyres.2006.05.013_bib32","first-page":"56","article-title":"Efficacy and safety of levetiracetam 3000mg\/d as adjunctive treatment in adolescents and adults suffering from idiopathic generalised epilepsy with myoclonic seizures","volume":"46","author":"Verdru","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2006.05.013_bib33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0920-1211(97)00080-6","article-title":"Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide","volume":"29","author":"Wallace","year":"1998","journal-title":"Epilepsy Res."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121106001616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121106001616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:17:14Z","timestamp":1760275034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121106001616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0920121106001616"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2006.05.013","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2006.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}